Efficacy and safety of iguratimod on patients with relapsed or refractory IgG4-related disease

Volume: 39, Issue: 2, Pages: 491 - 497
Published: Dec 17, 2019
Abstract
To evaluate the therapeutic efficacy and safety of iguratimod on patients with relapsed or refractory IgG4-related disease (IgG4-RD). We conducted a retrospective single-center study in 17 IgG4-RD patients admitted to Peking University People’s Hospital. Patients were given iguratimod, 25 mg, twice daily and clinical data were collected at 0, 12, and 24 weeks. The baseline treatments include prednisone, cyclophosphamide, leflunomide,...
Paper Details
Title
Efficacy and safety of iguratimod on patients with relapsed or refractory IgG4-related disease
Published Date
Dec 17, 2019
Volume
39
Issue
2
Pages
491 - 497
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.